Last reviewed · How we verify
Polydeoxyribonucleotides
At a glance
| Generic name | Polydeoxyribonucleotides |
|---|---|
| Also known as | PDRN, PLACENTEX |
| Sponsor | Seoul National University Hospital |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Comparative Study for Facial Scar Remodeling Using Fractional Carbon Dioxide Laser Combined With PDRN Versus Fractional CO₂ Laser (PHASE2)
- Microneedling for Skin Heath (PHASE4)
- Regenarative Treatment of Periocular Wrinkles With PDRN (NA)
- Hyaluronic Acid and Polynucleotides for Supra-bony Defects (NA)
- Polydeoxyribonucleotide for Elbow Lateral Epicondylitis (NA)
- Vaginal Biorevitalization With Polydeoxyribonucleotides for the Improvement of the Genitourinary Syndrome of Menopause (NA)
- Polydeoxyribonucleotide (PDRN) for Cuff Regeneration (PHASE4)
- Effect of PDRN in Post-operative Scars (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Polydeoxyribonucleotides CI brief — competitive landscape report
- Polydeoxyribonucleotides updates RSS · CI watch RSS
- Seoul National University Hospital portfolio CI